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Background: Despite the increasing frequency of liver resection for multiple types of disease, caudate lobe
resection remains a rare surgical event. The goal of this study is to review our experience and evaluate possible
predictors of adverse outcomes in patients undergoing caudate lobectomy.
Methods: We reviewed a 1,900-patient prospective hepato-pancreatico-biliary database from January 2000 to
December 2011, identifying 36 hepatectomy patients undergoing caudate lobe resection. Clinicopathologic
characteristic and outcome data were compared using chi-square, T-test, ANOVA, Kaplan-Meier, and Cox regression
analysis. Primary endpoints were the incidence and severity of complications, and secondary endpoints were blood
loss, hospital stay, and transfusion requirements. Patients were also divided in two groups with group A being
patients operated on before December 2007 and group B after 2007. We compared the demographics, risk factors,
complication rates, and operative details between the two groups.
Results: Thirty-six patients underwent caudate lobe resection for cholangiocarcinoma (47.2%), metastatic colorectal
cancer (36.1%), hepatocellular carcinoma (8.3%), or benign disease (8.3%). Nine patients (29%) had additional liver
resection. Median overall survival (OS) was 21 months. Complications occurred in 52.7% (19/36) of patients with a
median grade of 2. Tobacco abuse was associated with an increased risk of operative complications (73.3% vs.
38.9%, p = 0.03). Prior history of cardiac disease was associated with a higher complication rate (87% vs. 42%,
p = 0.03). Neoadjuvant chemotherapy, biliary procedures, hepatitis, and prior major abdominal surgery were not
predictive of complications. Major complication was also predicted by the volume of RBC transfusion (2.7 vs. 4.1
units, p = 0.003). In our subgroup analysis of the patients undergoing surgery before and after 2007, the two
groups were well matched based on age, comorbidities, and risk factors. The complication rates and rates of
high-grade complications were similar, but blood loss (600 ml vs. 400 ml, p = 0.03), inflow occlusion time (Pringle
time 12.6 vs. 6, p = 0.00), and hospital stay (9.5 vs. 7 days, p = 0.01) were significantly lower in group B.
Conclusions: With appropriate patient selection, caudate lobe resection is an effective component of surgery for
hepatic disease. Tobacco use and prior cardiac history increase the risk of complications.
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In the last 2 decades there have been dramatic im-
provements in the morbidity, mortality, and long-term
outcomes in hepatic surgery. Improved surgical tech-
niques, new instrumentation, and low central venous
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reproduction in any medium, provided the oras well as increased the number of patients eligible for
curative hepatectomy for a number of diseases [1]. This
is especially true for malignancy with subsequent im-
proved survival for patients undergoing hepatectomy
for metastatic colorectal cancer (MCRC) [2], hepato-
cellular carcinoma (HCC) [3], and cholangiocarcinoma
[4]. This in turn has led to an increase the number of
successful hepatectomies for longer-term disease control.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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caudate lobe resection remains low because of a combi-
nation of factors. The unique anatomic location and spe-
cific anatomic features of the caudate lobe render
resection technically challenging [5-7]. In addition, the
blood supply of the caudate further complicates resec-
tion because of the difficulty of vascular isolation with
ongoing dialogue as to the best surgical technique and
true vascular anatomy of this region [8,9]. Special care
must be taken regarding the caudate lobe’s close proxim-
ity to the middle hepatic vein, retrohepatic caval attach-
ments, and left-hepatic arterial supply. As a result of
these factors, modern caudate lobectomy has only re-
cently been initially described [10]. Since that time,
caudate lobectomy has increased in frequency and has
been shown to be an effective treatment for HCC [11],
MCRC [12,13], and cholangiocarcinoma [4]. However,
the vast majority of data are reported from smaller series
or non-Western populations [14].
Given the current paucity of data, this study attempts
to review the available data following caudate resection
from our tertiary referral center. The goal was to review
our data and delineate pathologic and clinical factors po-
tentially associated with adverse outcomes for patients
undergoing caudate lobectomy.
Methods
We performed a review of a 1,900-patient prospective
hepato-pancreato-biliary database spanning from January
2000 to December 2011. Patients were included if they
underwent caudate lobectomy for any indication. Pa-
tients were included if they had concurrent hepatectomy
or other organ resection. Patient selection and operative
technique were the same as has been presented previ-
ously [15-19]. Patients were excluded for incompleteness
of data or age <18 years. The university IRB approved this
study. We evaluated potential outcome predictors with
one primary endpoint: development of postoperative com-
plications. Secondary endpoints assessed were require-
ment of blood transfusion, hospital stay, and the number
of blood products transfused. We attempted to analyze re-
currence, but the data for this analysis were not available/
incomplete in the majority of patients. Complications were
graded according to CTCAE v4.0 criteria [20]. A severe-
grade complication was defined as one that was of grade
≥3, with a maximum complication grade of 5 (i.e., requir-
ing intervention, either operative or radiologic).
In order to analyze the impact on the outcome over
different periods in time, patients were divided into two
groups according to the year of operation, namely before
2007 and after. We chose 2007 as an arbitrary cutoff
point based on our change in practice of liver transec-
tion technique transitioning from a crush-clamp and clip
model to a simultaneous precoagulation and transectiondevice. With our increasing experience with laparoscopic
liver resections, this was also around the time that we
abandoned routine use of inflow control (Pringle) and
an increasing number of patients had received modern
chemotherapy (including FOLFOX). Eighteen patients
each underwent caudate lobe resections before and after
December 2007. We similarly compared outcomes in-
cluding complications, high-grade complications, opera-
tive times, and intraoperative blood loss between the
two groups.
Data were analyzed using chi-square, Fisher’s exact, in-
dependent T, Kaplan-Meier, and Cox regression tests
utilizing SPSS (Chicago, IL, USA). A p-value < 0.05 was
considered statistically significant.
Results
Thirty-six patients underwent caudate lobectomy over
this 11-year period reviewed. Of these, the majority was
for MCRC (n = 16, 44.4%) or cholangiocarcinoma (n =
14, 38.9%), with the remainder for either HCC or benign
disease (n = 3, 8.3% each). Tweenty-two were male
(61.1%). Median age at presentation was 61, with 30.5%
having concomitant cardiopulmonary disease. Tobacco
abuse was present in 15 (41.7%) patients, and among to-
bacco smokers, the median usage was 21 pack years
(IQR 12–31). History of alcohol abuse was seen in seven
patients (19.4%).
Complications were seen in 19 out of 36 patients
(52.7%), of whom 8 (22.2%) were high grade, requiring
additional intervention. Factors associated with compli-
cations as well as with high-grade complications were
analyzed (Table 1) using univariate and multivariate ana-
lysis. The most common complication was ileus (10.8%).
Significant hepatic complications were infrequent: two
patients developed biliary complications, two bilomas,
and one bile leak. In addition, only two patients suffered
from perioperative liver insult, neither of whom had per-
manent liver failure.
Tobacco abuse was associated with an increased risk of
postoperative complications (73.3% vs. 38.9%, p = 0.04). A
history of prior cardiac disease (n = 8) was associated with
an increased overall complication rate (87% vs. 42%, p =
0.03) but not high-grade complications, hospital stay, or
mortality. Multivariate analysis also showed an association
of increased complication rates with tobacco use (OR =
1.7, p = 0.05 with CI 0.2-2.7) and a history of cardiac dys-
function (OR = 1.9, p = 0.03 with CI 0.7-4.1). Among the
other comorbidities, three patients (8.3%) had a history of
viral hepatitis, but only one patient had ascites/cirrhosis at
the time of resection. Other medical comorbidities did not
predict outcomes for morbidity or mortality.
With regards to presenting complaints, the majority
(n = 13, 34.7%) were related to biliary obstruction or stasis,
with 14 (38.9%) requiring preoperative biliary decompression.
Table 1 Factors associated with complications
Factor Any complication, n = 19 High-grade complication, n = 8 P-value^
Alcohol abuse 5 (13.9%) 1 (2.8%) 0.25/0.5
Cardiac h/o (n = 8 22.2%) 7 (19.4%) 2 (5.6%) 0.03/0.5
Tobacco abuse (n = 15 41.7%) 11 (30.6%) 4 (11.1%) 0.04/0.4
Hepatitis (n = 3 8.3%) 2 (5.6%) 0 0.9
Left lobectomy 4 (11.1%) 0 0.1/0.1
Right lobectomy 6 (16.7%) 2 (5.6%) 0.09/0.1
Colectomy 6 (16.7%) 5 (13.9%) 0.17/0.2
Transfusion 9 (25%) 2 (5.6%) 0.3/0.1
Number of units pRBC (median) 2.7 4.1 0.1/0.003
Number of lesions removed (mean) 2.2 3.5 0.04/0.8
^p value: Significance using univariate analysis: Fisher’s exact and chi-square test for categorical and independent group t test for numerical variables. Numbers in
bold are for significant values. The first value is the p value for all complications, and second value is for high-grade complications.
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rapy with 19 (52.7%) receiving adjuvant therapy. Neoadjuvant
therapy was also not associated with an increased risk of
complications (9 had complications, p = 0.3).
Operative times ranged from 80–360 min (median 180
min, IQR 140–237.5). Median intraoperative blood loss
was 450 ml (IQR 300–800); central venous pressure
(CVP) at the time of parenchymal transection was 2 (IQR
1–5). In ten patients (27.8%) Pringle inflow vascular con-
trol was used. Blood transfusion was given in 20 patients
(55.6%). Vascular reconstruction was done in five patients
(2 HCCs, 2 MCRCs, 1 cholangiocarcinoma) with three
(9.7%) portal vein reconstructions and two caval recon-
structions. Resection margins were microscopically posi-
tive (R1) in the final specimen in 22.2% (n = 8). The
majority of these positive margins occurred in patients
with cholangiocarcinoma with 75% of positive margins oc-
curring in this group (p = 0.041).
Isolated caudate resection was performed in 22 pa-
tients (61.1%). Concurrent, non-caudate hepatectomy
was performed in 14 patients; 7 each had a left or right
lobectomies (19.4% each), including 7 patients who un-
derwent a trisegmentectomy (19.4%). Patients with a
diagnosis of mCRC were compared with patients with
cholangiocarcinoma and were noted to have a signifi-
cantly shorter hospital stay (8.3 vs. 13.3 days, p = 0.010),
significantly lower blood transfusion requirements (37%
vs. 62%, p = 0.05), and significantly lower positive mar-
gin rates (6.8% vs. 42.8%, p = 0.03). They were also
found to have lower overall complication rates (50% vs.
71%, p = 0.07), shorter operative times (173 min vs. 203
min, p = 0.4), and less blood loss (540 ml vs. 626 ml, p =
0.21), but this did not reach statistical significance.
One perioperative death was seen in an 87-year-old
woman undergoing caudatectomy for palliation, 4 years sta-
tus post-sigmoidectomy, for CRC receiving 10 units of peri-
operative RBCs. Subsequently, she developed complicationsfrom a percutaneous gastrostomy and was never able to re-
cover from this, succumbing to multiorgan system failure
within a few days.
The median number of lesions (p = 0.2) removed did
not predict the development of a complication. Complica-
tion was also unaffected by the performance of common
bile duct resection (p = 0.1); the interaction of bile duct re-
section as well as the diagnosis of cholangiocarcinoma was
not a confounder in this analysis (p = 0.7). The need for
transfusion did not predict complication (42% vs. 58%, p =
0.3), but trended toward a higher rate of high-grade com-
plications with the mean number of units transfused far
greater in those patients developing a high-grade compli-
cation (2.8 vs. 6.6, p = 0.007).
Predominant pathologic findings of the normal peritu-
moral hepatic parenchyma had the majority of inflamma-
tory findings: inflammatory 36%, fibrosis 11%, steatosis
17%, and normal 25%. Inflammatory pathology trended
toward increased operative times (165 vs. 202 min, p =
0.1) and blood loss (430 vs. 690 ml, p = 0.06), but this dif-
ference did not reach statistical significance.
With regards to the subset of the 22 patients who
only underwent isolated caudate lobectomy, 9 each
(41%) were for MCRC and cholangiocarcinoma. Their
age and distribution of comorbidities were similar to
those of the larger cohort. Complications were seen in
9 of 22 patients (41%), of which 6 (27.3%) were high
grade, requiring additional intervention. Tobacco use
(62.5% vs. 28.6, p = 0.08) and a history of prior cardiac
disease (67% vs. 35%, p = 0.07) were associated with an
increased overall complication rate, which was not sta-
tistically significant. Operative time (median 160, IQR
120–232), intraoperative blood loss (median 350, IQR
225–500), CVP (median 3, IQR 2–6), patients receiving
blood transfusions (n = 14, 63.6%) and the number of
transfusions in patients receiving them (2, IQR 0–3),
R1 resections (n = 5, 22.7%), and overall hospital stay
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ger cohort.
We then analyzed the potential differences between
two subgroups of patients undergoing operations on
(group A) or before (group B) December 2007 (Table 2).
There were 18 patients in each group, and these patients
were similar in median age (64.1 and 60.3 years), cardio-
pulmonary comorbidities, diagnosis, type of procedure
performed, and number of tumors removed (1.67 vs. 1).
Median OS was 19 months for group A and 21 for
group B (p = 0.8).
Complication rates and high-grade complication
rates were similar in both groups with group A having
a 5% higher complication rate (55% vs. 50% for B, p =
0.9). The two groups were analyzed for factors asso-
ciated with an increased complication rate (Table 2).
Median operative times were similar (group A: 180
min and group B: 192 min, p = 0.38). Median in-
traoperative blood loss in group A was 600.3 ml versus
400 ml in group B, which was statistically significant
with a p value of 0.03. However, the transfusion re-
quirements and total number of units received were
not significantly different. Of note, the median CVP at
parenchymal transection was 3 in group A vs. 2 in
group B (p = 0.08). Median length of stay in the hos-
pital was significantly longer at 9.5 days before 2007 as
compared to 7 days after 2007 (p = 0.01). A similar
number of margins were positive before and after 2007
(3 vs. 5, p = 0.6), and a similar number of patients had
undergone a prior colectomy.Table 2 Subgroup temporal analysis: peri- and
postoperative analysis






Complications 10 (55.5%) 9 (50%) 0.9
High-grade
complications







Blood loss 600 ml 400 ml 0.03








Pringle time 12.6 min 6.3 min 0.00
Hospital stay 9.5 days 7 days 0.01
Positive tumor
margins
3 (16.6%) 5 (27.8%) 0.7Discussion
Caudate lobe resection is a challenging operation with
evolving techniques. The caudate lobe can be involved as
the primary liver lesion of an isolated metastatic site.
In view of its intimate relationship with the inferior vena
cava and the portal vein, presence of multiple short caud-
ate veins, and posterior location, it is difficult to resect.
Caudate lobe resection can be done in isolation or com-
bined with left or right lobectomies depending on the dis-
ease burden. In view of the paucity of data in the Western
literature, we reviewed our experience over the last decade.
The majority of caudatectomies performed were either for
MCRC or cholangiocarcinoma. Tobacco use and a prior
history of cardiac disease were independent predictors of
morbidity on uni- and multivariate analysis. Neoadjuvant
chemotherapy, prior colectomy, and blood transfusions
had no significant effect on complication rates. Develop-
ment of high-grade complications was higher in patients
undergoing right lobectomies with caudatectomies, but
this did not reach statistical significance. The performance
of prior colectomy did not impact the complication rate or
the incidence of high-grade complications. Similarly, the
need for blood transfusions did not correlate with higher
complication rates in our study. We also looked at the
pathologic findings of the peri-tumoral hepatic paren-
chyma and found that inflammatory pathology trended to-
ward increased operative times and blood loss. This could
be a reflection of the native background hepatic disease or
a reflection of prior adjuvant therapy such as hepatotoxic
chemotherapy or arterial embolization therapy.
Our subgroup analysis comparing patients undergoing
caudate resections before 2007 to those after was carried
out to gain a better insight into the temporal trends of
performance and factors affecting them over time. This
arbitrary division at December 2007 was made because
it was approximately midway in the study period and di-
vided the study population into two equal and relatively
well-matched groups. The two groups were similar in
comorbidities, age, and primary diagnosis. We noted an
improvement in complication rates, hospital stays, and
operative times; however, these did not reach statistical
significance. Blood loss was significantly lower in the
latter group, and this could be attributed to a lower pa-
renchymal transection CVP in the later years (which
showed a lower trend in the second half but was not sta-
tistically significant). We attribute this improvement in
these parameters to a combination of factors including
more uniform use of improved energy devices for paren-
chymal transection and improved implementation of
controlled CVP. The total Pringle time in patients
requiring it was significantly lower in the latter group,
and this along with the overall more expedient outcome
(lower operative times, shorter stays) is once again pro-
bably due to a confluence of many factors. Our experience
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liver resections has led to a decreased use of inflow occlu-
sion (Pringle maneuver). This was in part due to better
parenchymal transection technology with less blood loss
and adaptation to intraparenchymal inflow and outflow
control with stapling as an evolution to minimally invasive
liver resections.
There has been a paucity of studies in the Western lit-
erature on the outcomes and predictors associated with
caudate lobectomy. This article is an attempt to fill the
lacuna and better understand the factors affecting the
selection, distribution, and morbidity of caudate resec-
tions. The majority of reports have been similar in scope,
between approximately 20 to 50 patients undergoing
caudate resection [11-13,21-23]. The median operative
time within these series varies from 230–400 min, sig-
nificantly higher than our median of 180 min (Table 3).
Whether this is due to technique or variability of the
disease pattern cannot be readily discerned because of
the variance among the data, but it is likely that both
contribute. Similar comparison can be made between
the amount of intraoperative blood loss, with several
series reporting an average EBL of 1,200 ml [23], 1,590
ml [24], and 1,683 ml [22], respectively, whereas the EBL
in our series was lower (450 ml). Interestingly, few stud-
ies reported their rate of perioperative complications,
and fewer still graded the complication rates. The rate of
major complications we experienced, again, was similar
to that seen by others [12]. Hawkins et al. [25] also
showed that major vascular resection was predictive of
poorer overall survival (OS); this was not evaluable in
our series with so few (n = 5) undergoing portal or caval
reconstruction.
The novelty of these series, including our own, is tem-
pered by their retrospective nature as well as potential
selection bias. Specifically, our own series included only
one patient with significant cirrhosis/ascites so as be
classified as a Child’s class B cirrhotic, making this study
not generalizable to the entire population of patients
with severe hepatic disease or malignancy. Also theTable 3 Caudatectomy series comparison
Author n Pathology OR time EBL %Morbidity
Philips 36 Mixed 180 450 52.7%
Hawkins [25] 150 Mixed 317 800 55.3%
Liu [11] 114 HCC NA 18%
Morise [26] 8 CRC 315 1,325 12.5%
Sakoda [22] 12 HCC 400 1,683 8.3%
Sarmiento [27] 19 Mixed 211 760 5%
Wen [21] 11 HCC NA 300 54.5%
Zuo [28] 16 HCC 255 740 NA
Mixed = combined MCRC, HCC, and cholangiocarcinoma. EBL = estimated
blood loss in ml.number of patients with a history of hepatitis is under-
represented. However, this bias will be inherent regard-
less given the nature of caudate resection, as one would
be remiss in subjecting a patient with advanced hepatic
disease to this type of resection knowing the potential
for postoperative morbidity and mortality. The patho-
logy in our study was mixed such that meaningful data
for long-term survival analysis and recurrence rates would
be hard to interpret. Also, we acknowledge that different
biologies requiring caudate resections led to differences in
operative techniques and outcomes. Cholangiocarcinoma
often requires concurrent bile duct resection as well as
more preoperative biliary decompression, which changes
the morbidity profile of these resections. Similarly, colo-
rectal metastasis and hepatocellular carcinoma in the
caudate lobe tend to have greater vascular invasion, as
was seen in our study. Despite these limitations, this
study provides meaningful insight into the safety of
caudate resections as well as delineation of the risk
factors. Modern hepatic surgery is ever evolving with
improvement in perioperative mortality and morbidity
over the years. This trend is reflected in our series.
Better transections techniques, improved preoperative
planning adjuncts, and ever evolving and improving
surgical techniques inherent to complex surgery such as
caudatectomies are reflected in our temporal subgroup
analysis. None of the patients in this series underwent
laparoscopic caudate lobe resections, which recent pub-
lications suggest is being performed in high-volume
centers and is feasible [29,30].Conclusion
In summary, caudate lobectomy is a safe and viable
means of operative treatment for benign or malignant
hepatic disease, though it remains technically demand-
ing. Complications in caudatectomy are associated with
more advanced disease and tobacco use. Mortality is
similarly associated with more advanced disease as well
as the presence of inflammatory findings on hepatic bi-
opsy. Further analysis is needed to determine which
factors are truly associated with disease-specific out-
comes for caudate resection given the paucity of de-
scriptive literature.Competing interests
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